Bank Of New York Mellon Corp Cardiff Oncology, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$1.45 - $2.09 $20,807 - $29,991	14,350 New	14,350 $23.7 Million
Q4 2022 Feb 14, 2023	BUY	$1.22 - $1.66 $17,507 - $23,821	14,350 New	14,350 $20,000
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $207 - $433	-135 Reduced 0.93%	14,350 $22,000
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $118,060 - $263,364	-100,906 Reduced 87.45%	14,485 $32,000
Q1 2022 May 11, 2022	SELL	$2.11 - $7.25 $10,518 - $36,141	-4,985 Reduced 4.14%	115,391 $286,000
Q4 2021 Feb 11, 2022	BUY	$5.18 - $7.24 $43,097 - $60,236	8,320 Added 7.42%	120,376 $723,000
Q3 2021 Nov 12, 2021	BUY	$5.01 - $7.58 $39,318 - $59,487	7,848 Added 7.53%	112,056 $746,000
Q2 2021 Aug 11, 2021	BUY	$6.65 - $10.04 $597,562 - $902,184	89,859 Added 626.24%	104,208 $692,000
Q1 2021 May 13, 2021	SELL	$9.1 - $19.57 $13,349 - $28,709	-1,467 Reduced 9.28%	14,349 $132,000
Q4 2020 Feb 09, 2021	SELL	$12.02 - $24.71 $560,228 - $1.15 Million	-46,608 Reduced 74.66%	15,816 $284,000
Q3 2020 Nov 12, 2020	BUY	$4.25 - $14.19 $265,302 - $885,796	62,424 New	62,424 $885,000

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $175M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.